The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Growth Is Projected For The Drugs for Immunotherapy Market During The Forecast Period 2026–2030?
The size of the drugs for immunotherapy market has expanded rapidly in recent years. It is projected to increase from $310.48 billion in 2025 to $349.53 billion in 2026, at a compound annual growth rate (CAGR) of 12.6%. This historical growth can be attributed to factors such as limited immunotherapy options, a reliance on conventional cancer treatments, the growing incidence of cancer and autoimmune diseases, an increase in clinical trials for monoclonal antibodies, and rising healthcare infrastructure.
The market size for immunotherapy drugs is anticipated to witness substantial growth over the next few years. It is projected to expand to $570 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.0%. The expansion during the forecast period can be ascribed to the creation of bispecific and conjugated antibodies, the widening reach of personalized immunotherapy, the increasing embrace of checkpoint inhibitors, growing investments in therapeutic vaccine research, and the incorporation of digital patient monitoring and AI-guided immunotherapy. Significant trends expected in this period include a rising acceptance of monoclonal antibodies and checkpoint inhibitors, progress in cancer immunotherapy and autoimmune disease treatments, intensified development of therapeutic and preventive vaccines, the broadening application of t-cell receptor and cytokine-based therapies, and the integration of immunotherapy into both ambulatory and hospital care.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2559&type=smp
Which Economic Or Industry Drivers Are Impacting The Drugs for Immunotherapy Market?
Rising healthcare spending is anticipated to propel the growth of the drugs for immunotherapy market going forward. Healthcare expenditure refers to the entire sum of money dedicated to healthcare goods and services within a specific region or country over a given period, including outlays for doctor visits, hospital stays, surgeries, diagnostic procedures, and various treatments. These financial resources, constituting health care expenditure, are allocated by individuals, healthcare providers, insurance companies, and government agencies to cover the costs linked to drugs for immunotherapy and other treatments. For instance, in December 2024, the Centers for Medicare & Medicaid Services, a US-based agency responsible for administering the Medicare and Medicaid programs, reported that in 2023, U.S. health care expenditures increased by 7.5%, climbing to $4.9 trillion, or roughly $14,570 for each individual. Therefore, the increasing healthcare expenditure is driving the growth of the drugs for immunotherapy market.
What Market Segments Are Evaluated Within The Drugs for Immunotherapy Market?
The drugs for immunotherapy market covered in this report is segmented –
1) By Type: Monoclonal Antibodies, Interferons, Interleukins, Vaccines, Checkpoint Inhibitors, Other Types
2) By Therapy Area: Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases, Other Therapy Areas
3) By End User: Hospitals & Clinics, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies
2) By Interferons: Interferon Alfa, Interferon Beta, Interferon Gamma
3) By Interleukins: Interleukin-2 (IL-2), Interleukin-6 (IL-6), Interleukin-12 (IL-12)
4) By Vaccines: Preventive Vaccines, Therapeutic Vaccines
5) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors
6) By Other Types: Cancer Cell Therapies, Cytokine Therapy, T-Cell Receptor Therapy
What Industry Trends Are Redefining The Drugs for Immunotherapy Market?
Leading companies in the drugs for immunotherapy market are prioritizing the creation of innovative products, such as Keytruda (pembrolizumab), to deliver reliable services to customers. Keytruda (pembrolizumab) is an immunotherapy that incorporates a targeted therapy drug known as an immune checkpoint inhibitor, intended for adult patients. For instance, in January 2023, Merck & Co., Inc., a pharmaceutical company based in the US, introduced Keytruda (pembrolizumab) after receiving approval from the Food and Drug Administration, a US federal agency. Keytruda (pembrolizumab) immunotherapy functions by collaborating with the immune system to assist in fighting cancer cells, thereby treating various types of cancer. Furthermore, KEYTRUDA (pembrolizumab) is approved for use as an adjuvant treatment for non-small cell lung cancer (NSCLC). This marks a crucial progression in cancer treatment and is projected to have a favorable effect on the healthcare industry.
Who Are The Top Market Participants Influencing The Drugs for Immunotherapy Market?
Major companies operating in the drugs for immunotherapy market are F. Hoffmann-La Roche Ltd., Novartis AG, Merck & Co. Inc., UbiVac, Bayer AG, Celgene Corporation, Incyte Corporation, Juno Therapeutics Inc., Bluebird bio, Celldex Therapeutics, BeiGene, BioNTech AG, CytomX Therapeutics, Eisai Co. Ltd., Flexus Biosciences Inc., Genscript Biotech Corporation, Harpoon Therapeutics Inc., Heptares Therapeutics Ltd., Ignyta Inc., Immatics Biotechnologies, Jounce Therapeutics Inc.
Read the full drugs for immunotherapy market report here:
https://www.thebusinessresearchcompany.com/report/drugs-for-immunotherapy-global-market-report
What Are The Top-Performing Regions Within The Drugs for Immunotherapy Market?
North America was the largest region in the immunotherapy market in 2025. Middle East is expected to be the fastest growing region in the drug for immunotherapy market report during the forecast period. The regions covered in the drugs for immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Drugs for Immunotherapy Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=2559&type=smp
Browse Through More Reports Similar to the Global Drugs for Immunotherapy Market 2026, By The Business Research Company
Immunosuppressant Market Report 2026
https://www.thebusinessresearchcompany.com/report/immunosuppressant-global-market-report
Immunoglobulins Market Report 2026
https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report
Immunofluorescence Assay Market Report 2026
https://www.thebusinessresearchcompany.com/report/immunofluorescence-assay-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model